Rebetol and Hypersensitivity - a phase IV clinical study of FDA data

Summary:

Hypersensitivity is reported as a side effect among people who take Rebetol (ribavirin), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Peg-Intron, and have Hepatitis c.

The phase IV clinical study analyzes which people have Hypersensitivity when taking Rebetol. It is created by eHealthMe based on reports of 25,907 people who have side effects when taking Rebetol from the FDA, and is updated regularly.

What is Rebetol?

Rebetol has active ingredients of ribavirin. eHealthMe is studying from 25,932 Rebetol users. Check the latest studies of Rebetol.

What is Hypersensitivity?

Hypersensitivity is found to be associated with 2,748 drugs and 2,916 conditions by eHealthMe. Check the latest studies of Hypersensitivity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

25,907 people reported to have side effects when taking Rebetol.
Among them, 105 people (0.41%) have Hypersensitivity.

Among these 105 people:

* Approximation only. Some reports may have incomplete information.

Do you take Rebetol and have Hypersensitivity?

- Check whether Hypersensitivity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rebetol:

Rebetol (25,932 reports)

Hypersensitivity treatments and more:

Hypersensitivity (272,618 reports)

How severe was Hypersensitivity and when was it recovered:

Hypersensitivity in Rebetol

Expand to all the drugs that have ingredients of ribavirin:

Hypersensitivity and drugs with ingredients of ribavirin (566 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Rebetol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypersensitivity:

Hypersensitivity (2,748 drugs)

Browse all the conditions that are associated with Hypersensitivity:

Hypersensitivity (2,916 conditions)

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on ribavirin (the active ingredients of Rebetol) and Rebetol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.